
Medeia offers unique and well protected preclinical product candidates to strengthen and enhance partners’ R&D pipelines. Our team has a proven track record in delivering significant business opportunities to pharmaceutical and biotech companies.
We are known for innovativeness, scientific competence and successful management of drug discovery projects. We see partnerships as active alliances and are always ready to contribute breakthrough solutions to joint projects.
Being a semi-virtual and cost-effective company, Medeia has built a strong academic and corporate network to help accomplish our goals. We are open to discuss all types of transactions from joint research projects with option-based arrangements to straight out-licensing deals.
Medeia Therapeutics Ltd has been awarded a 0,65 million euro grant from Young Innovative Company (YIC) program financed by Tekes.
Read more...
Medeia Therapeutics receives significant support from Finnish Funding Agency for Technology and Innovation (Tekes)
Read more...
Medeia Therapeutics announces the second financing round led by Inveni Capital
Read more...